Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy
Status:
Terminated
Trial end date:
2016-03-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to test the safety and tolerability of different,
increasing doses of an experimental medication called HT-100 in boys and young men with
Duchenne muscular dystrophy (DMD). The study medication, HT-100, is a medicine that may help
promote healthy muscle regeneration, diminish inflammation and the resulting damage to
muscle, and decrease the scar tissue that forms in the muscles of children with DMD. In this
study, pharmacokinetic sampling, or measurements of the amount of HT-100 in the bloodstream
will also be taken.